Here we report that ovarian cancer-an aggressive malignancy that is refractory to standard treatments and current immunotherapies 5-8 -induces endoplasmic reticulum stress and activates the IRE1α-XBP1 arm of the unfolded protein response 9,10 in T cells to control their mitochondrial respiration and antitumour function. In T cells isolated from specimens collected from patients with ovarian cancer, upregulation of XBP1 was associated with decreased infiltration of T cells into tumours and with reduced IFNG mRNA expression. Malignant ascites fluid obtained from patients with ovarian cancer inhibited glucose uptake and caused Nlinked protein glycosylation defects in T cells, which triggered IRE1α-XBP1 activation that suppressed mitochondrial activity and IFNγ production. Mechanistically, induction of XBP1 regulated the abundance of glutamine carriers and thus limited the influx of glutamine that is necessary to sustain mitochondrial respiration in T cells under glucosedeprived conditions. Restoring Nlinked protein glycosylation, abrogating IRE1α-XBP1 activation or enforcing expression of glutamine transporters enhanced mitochondrial respiration in human T cells exposed to ovarian cancer ascites. XBP1deficient T cells in the metastatic ovarian cancer milieu exhibited global transcriptional reprogramming and improved effector capacity. Accordingly, mice that bear ovarian cancer and lack XBP1 selectively in T cells demonstrate superior antitumour immunity, delayed malignant progression and increased overall survival. Controlling endoplasmic reticulum stress or targeting IRE1α-XBP1 signalling may help to restore the metabolic fitness and antitumour capacity of T cells in cancer hosts.
demonstrated increased XBP1 mRNA splicing, compared with peripheral T cells from women who are free of cancer ( Fig. 1a, b ). XBP1 levels in intra-tumoral T cells were correlated with expression of HSPA5 and DDIT3, which are genes that indicate activation of the unfolded protein response (UPR); this suggests that these cells experience ER stress in situ ( Fig. 1c ). Increased expression of XBP1, HSPA5 and DDIT3 was associated with reduced T cell infiltration in the specimens that we analysed ( Fig. 1d ). However, only XBP1 expression correlated with decreased IFNG levels in intra-tumoral T cells ( Fig. 1e ), which suggests that IRE1α-XBP1 activation driven by ER stress might influence T cell functions in ovarian cancer.
XBP1 splicing was observed mainly in T cells present in ovarian cancer ascites ( Fig. 1b) , which is an immunomodulatory and tumorigenic fluid that often accumulates in patients with metastatic or recurrent disease 6, 15 . We exploited this milieu to examine whether ovarian cancer induces IRE1α-XBP1 in T cells to control their activity. We focused on CD4 + T cells because they are the predominant leukocyte population in ovarian cancer ascites [16] [17] [18] [19] , and because the mechanisms regulating their protective capacity in this setting remain unclear. Preactivated CD4 + T cells from women who are free of cancer exhibited a dose-dependent increase in XBP1 upon treatment with cell-free supernatants of ascites from patients with ovarian cancer (Extended Data Fig. 1a ). Analyses based on fluorescence-activated cell sorting (FACS) confirmed the induction of XBP1s in response to exposure to ascites ( Fig. 2a, b ). T cells treated with the ER stressor tunicamycin demonstrated strong XBP1s staining that was abrogated by the IRE1α inhibitor 4μ8C (Extended Data Fig. 1b ), validating the specificity of XBP1s detection by FACS. Hypoxia, acidic pH and nutrient deprivation disrupt ER homeostasis and trigger the UPR 11 . Although ovarian cancer ascites is hypoxic in vivo 20 , we observed XBP1s induction in T cells exposed to this fluid even under normoxia ( Fig. 2a, b ). The pH of independent ascites samples was within neutral range. Ascites treatment modestly augmented the levels of reactive oxygen species, but this effect was not responsible for XBP1 induction in T cells (Extended Data Fig. 1c, d) . Glucose is essential for N-linked protein glycosylation and, therefore, alterations in its availability can provoke ER stress 21 . No correlation was found between the ascites glucose concentration and XBP1 induction in CD4 + T cells (Extended Data Fig. 1e , f). However, ascites exposure suppressed expression of the major glucose transporter GLUT1 in CD4 + T cells ( Fig. 2c, d ). This result was consistent with the observation that T cells present in the ascites of patients with ovarian cancer demonstrate negligible GLUT1 surface expression Letter reSeArCH (Extended Data Fig. 1g ). Glucose uptake was therefore compromised in ascites-exposed CD4 + T cells, and this defect was associated with enhanced expression of XBP1 mRNA and of XBP1s ( Fig. 2e , Extended Data Fig. 1h ).
Protein glycosylation requires uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), which is generated through the hexosamine biosynthetic pathway using glucose as a substrate 21 . Ascites-exposed CD4 + T cells displayed N-linked protein glycosylation defects (Extended Data Fig. 1i , Extended Data Table 1 ), but supplementation with N-acetylglucosamine (GlcNAc)-which serves as direct substrate for N-linked glycosylation-attenuated XBP1 activation in this setting (Extended Data Fig. 1j ). Limited glucose uptake in this setting also dampened the glycolytic capacity of CD4 + T cells (Fig. 2f) . The oxygen consumption rates of ascites-exposed CD4 + T cells decreased in a dose-dependent manner (Fig. 2g, Extended Data Fig. 1k ), which suggests that this fluid disturbs mitochondrial activity. T cell mitochondrial respiration also diminished when protein N-linked glycosylation was directly inhibited using tunicamycin (Extended Data Fig. 1l, m) . Because pyruvate was always present in the culture medium, the mitochondrial perturbations observed were unlikely to be caused by reduced T cell glycolysis in the presence of ascites. Therefore, IRE1α-XBP1 activation might directly affect T cell mitochondrial function. Blocking IRE1α with 4μ8C inhibited induction of XBP1s (Fig. 2h ) while enhancing mitochondrial respiration in human CD4 + T cells exposed to ovarian cancer ascites ( Fig. 2i, Extended Data Fig. 1n ). IRE1α inhibition did not modulate glucose uptake or glycolysis in ascites-treated T cells (Extended Data Fig. 1o ), which confirms that impaired glucose import drives IRE1α-XBP1 activation. Attenuating XBP1s induction using GlcNAc (Extended Data Fig. 1j ) also augmented mitochondrial respiration in T cells treated with supernatants of ovarian cancer ascites (Fig. 2j, Extended Data Fig. 1p, q) . Thus, reduced glucose import by ascites-exposed T cells not only dampens glycolysis but also impairs N-linked protein glycosylation, leading to ER stress and mitochondrial dysfunction driven by IRE1α-XBP1.
We generated conditional knockout mice (Xbp1 f/f Cd4 cre ) to understand how XBP1 regulates T cell function (Extended Data Fig. 2a ). The absolute cell numbers in lymphoid tissues-as well as the frequency of thymocytes, peripheral CD4 + and CD8 + T cells, and their corresponding subsets-were unaltered upon ablation of XBP1 (Extended Data Fig. 2b-j) . Loss of XBP1 in T cells did not affect the proportions of other immune-cell populations in lymphoid tissues (Extended Data Fig. 2k , l). Mixed bone marrow chimaeras, using wild-type mice and mice that lack XBP1 in the entire haematopoietic compartment, demonstrated normal T cell reconstitution (Extended Data Fig. 2m ). Proliferation and cell-cycle progression was unaltered in CD4 + T cells that lack XBP1 (Extended Data Fig. 2n , o). XBP1 therefore appears to be dispensable for T cell development and baseline functions in naive mice.
Glucose starvation for 6 h triggered Xbp1 splicing and induction of gene markers for the UPR (Extended Data Fig. 3a ) in CD4 + T cells that had previously been activated through CD3 and CD28. Glutamine withdrawal alone did not induce IRE1α-XBP1 at the time point we analysed, which suggests that T cells primarily activate this pathway in response to glucose limitation. Mitochondrial respiration was comparable in wild-type and XBP1-deficient CD4 + T cells when glucose was present (Fig. 3a) . The maximal oxygen consumption rate in wild-type CD4 + T cells decreased by about 50% upon glucose withdrawal but XBP1-deficient CD4 + T cells demonstrated superior mitochondrial respiratory capacity in this condition ( Fig. 3a) , which supports our observations using IRE1α inhibition ( Fig. 2i ) or GlcNAc supplementation in ascites-exposed human CD4 + T cells ( Fig. 2j ). T cell mitochondrial structure, morphology or mass were not affected by XBP1 deficiency, and expression of PGC1α also remained unaltered even upon glucose withdrawal or glycolysis inhibition (Extended Data Fig. 2p -r). Thus, XBP1 might restrain the use of alternative carbon sources that support mitochondrial respiration in the absence of glucose.
Glutamine metabolism maintains the tricarboxylic acid (TCA) cycle in response to glucose deprivation or reduced pyruvate supply 22 . Blocking mitochondrial glutamine use in glucose-deprived CD4 + T cells further reduced their maximal oxygen consumption rate (Extended Data Fig. 3b ). Because glutamine consumption in haematopoietic cells depends on glucose availability 23 , we hypothesized that XBP1 activation under glucose restriction could affect this process. Glucose starvation impaired [U-13 C]glutamine uptake in wild-type CD4 + T cells, but XBP1-deficient T cells in the same condition exhibited superior glutamine import and use, as evidenced by increased 13 C enrichment in glutamine, glutamate and various TCA-cycle metabolites (Extended Data Fig. 3c -i). Consequently, glucose-deprived T cells that lack XBP1 maintained higher levels of total mitochondrial metabolite pools derived from [U-13 C]glutamine compared with their wild-type counterparts (Fig. 3b ). XBP1 therefore restricts glutamine influx in T cells under glucose starvation.
IRE1α-XBP1 activation can mediate the degradation of glutamine transporters under ER stress by activating the ER-associated degradation system [24] [25] [26] , probably as a strategy to dampen metabolism under adverse conditions. Glucose withdrawal decreased the protein levels of the glutamine transporters ASCT2, SNAT1 and SNAT2 in wild-type 
Fig. 1 | IRE1α-XBP1 activation in human T cells that infiltrate ovarian
cancer. a, XBP1 splicing assays for CD4 + or CD8 + T cells isolated from ascites or solid tumours of patients with ovarian cancer, or from blood of cancer-free female donors. XBP1s, spliced form; XBP1u, unspliced form. Data were generated from three independent experiments. b, Frequency of spliced XBP1 divided by total XBP1 in T cells sorted from the indicated sources (n = 8 per group). c-e, Pairwise analyses for sorted ovarian cancerassociated CD4 + (circles) and CD8 + (squares) T cells (n = 22 total). c, Expression of genes linked with ER stress responses. d, Proportion of CD45 + CD3 + T cells present in the ovarian cancer specimen versus expression of the indicated genes in T cells isolated from the matched specimen analysed. e, IFNG versus genes associated with ER stress responses, in each specimen analysed. n values correspond to biologically independent samples (b-e). One-way ANOVA with Tukey's post-test, boxes represent median ± interquartile range and whiskers indicate minimum and maximum (b); Spearman's rank correlation test, Spearman coefficient (r) with P value (two-tailed), 95% confidence intervals for all correlation analyses (c-e) are described in Supplementary Table 2 . a-g, T cells were activated by CD3 and CD28 stimulation for 16 h in the absence or presence of supernatants from ovarian cancer ascites, at the indicated concentrations. a, b, Histograms (a) and quantification (b) of XBP1s staining (n = 16); iso, isotype control; MFI, mean fluorescence intensity. c, SLC2A1 expression was determined by quantitative PCR (qPCR) (n = 48). d, Immunoblot and quantification of GLUT1 in ascitesexposed CD4 + T cells. Density of GLUT1 was normalized to ACTB, and data are shown as the relative expression compared with the untreated control (n = 4 for 10% and 50% ascites; n = 2 for 100% ascites, all from two independent experiments). e, Glucose uptake was assessed using 2-NBDG and XBP1 expression was determined in the same sample. Symbols depict ascites from three independent patients tested at increasing concentrations on CD4 + T cells from multiple donors (n = 37). f, g, Baseline extracellular acidification rate (ECAR) (f) and oxygen consumption rate (OCR) profile (g) of CD4 + T cells exposed to ascites (n = 16). h-j, CD4 + T cells were treated with 4μ8C (h, i) or GlcNAc (j) for 1 h and then stimulated by CD3 and CD28 for 16 h in the presence of 10% ascites. h, XBP1s determined by FACS (n = 7). i, OCR profile in 4μ8C-treated T cells exposed to ascites (n = 9). j, OCR for GlcNAc-treated T cells exposed to ascites (n = 5). Data are shown as mean ± s.e.m. (b-d, f, g, i, j). n values represent biologically independent samples (b-j). One-way ANOVA with Tukey's post-test (b); two-tailed Student's t-test (c, f); one-way ANOVA with Bonferroni's post-test (d). Spearman's rank correlation test, 95% confidence intervals −0.9076 to −0.6760 (e); two-tailed paired Student's t-test (h). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. FCCP, carbonyl cyanide-p-(trifluoromethoxy) phenylhydrazone; oligo, oligomycin; R/A, rotenone and antimycin. maximal OCR (f) in wild-type T cells treated with DMKG (n = 14). Data are presented as relative expression compared with wild-type T cells incubated in the presence of glucose (a, d, f). g, h, OCR profile (g) and maximal OCR (h) for SNAT1-overexpressing human CD4 + T cells exposed to ovarian cancer ascites (n = 4). Data are shown as relative expression compared with control-virus-transduced T cells that were not exposed to ascites. n values represent biologically independent samples (a, b, d, f, h). Data are shown as mean ± s.e.m. One-way ANOVA with Tukey's post-test (a, b, d); two-tailed paired Student's t-test (f, h). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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CD4 + T cells ( Fig. 3c, d ). However, their XBP1-deficient counterparts demonstrated higher transporter expression under the same conditions ( Fig. 3c, d ), which was confirmed by immunofluorescence confocal microscopy (Extended Data Fig. 4a, b ). Loss of XBP1 did not modulate expression of genes encoding glutamine carriers under glucose limitation (Extended Data Fig. 4c ), but treatment with the proteasome inhibitor MG132 restored SNAT1 levels in wild-type T cells that were experiencing ER stress owing to glucose limitation (Extended Data Fig. 4d, e ). These data suggest that XBP1 activation restricts glutamine influx in glucose-deprived CD4 + T cells by controlling the abundance of glutamine carriers, probably through post-translational regulatory mechanisms.
Cells catabolize glutamine into α-ketoglutarate to replenish TCAcycle intermediates and sustain mitochondrial respiration 22 . Treatment with dimethyl-α-ketoglutarate (DMKG), a cell-permeable analogue of α-ketoglutarate, improved maximal mitochondrial respiration in T cells under glucose restriction ( Fig. 3e, f ). Ascites-exposed human CD4 + T cells-unable to import glucose and demonstrating mitochondrial dysfunction driven by IRE1α-XBP1 ( Fig. 2 )-also showed reduced levels of glutamine transporters (Extended Data Fig. 5a, b ), but DMKG treatment was sufficient to increase their maximal respiratory capacity in this milieu (Extended Data Fig. 5c, d) . Furthermore, overexpressing SNAT1 (Extended Data Fig. 5e , f) markedly enhanced mitochondrial function in human CD4 + T cells exposed to ascites derived from patients with ovarian cancer (Fig. 3g, h) . These results indicate that glucose restriction causes T cell mitochondrial dysfunction through XBP1-mediated inhibition of glutamine influx, and that overexpressing glutamine transporters or supplementing glutaminederived TCA intermediates-such as α-ketoglutarate-can restore mitochondrial respiration in ascites-exposed T cells.
To evaluate the role of this pathway in vivo, we developed orthotopic ovarian cancer in female mice that lack XBP1 in T cells. CD4 + and CD8 + T cells isolated from ovarian tumours driven by p53 loss and mutant KRAS 27 -or from ascites and spleens of host mice bearing metastatic ovarian cancer that overexpresses Defb29 and Vegfa in the ID8 cell line (hereafter, 'ID8-Defb29/Vegfa') 28 -demonstrated marked overexpression of total and spliced Xbp1 transcripts, as well as robust induction of gene markers for the UPR (Extended Data Fig. 6a, b ). However, T cells associated with ovarian cancer did not present signs of regulated IRE1α-dependent mRNA decay (Extended Data Fig. 6c, d) .
Transcriptomic analyses, performed on CD4 + T cells residing in the ascites of mice bearing metastatic ID8-Defb29/Vegfa ovarian cancer 28 , 
Xbp1 Letter reSeArCH identified 151 differentially expressed genes in wild-type versus XBP1deficient CD4 + T cells. In the ascites, genes related to T cell activationsuch as Cd69, Cd44, Cd28 and Nfkb1-and mediators of anti-tumour immunity-such as Ccl5, Ifng, Klrk1 and Fasl-were upregulated in XBP1-deficient CD4 + T cells compared with their wild-type counterparts ( Fig. 4a ). These genes were not differentially expressed in wild-type versus XBP1-deficient splenic CD44 high CD62L low CD4 + T cells sorted from naive mice (Extended Data Fig. 7a ), which demonstrates a function for XBP1 that is context-specific in T cells associated with ovarian cancer. Loss of XBP1 did not cause regulated IRE1α-dependent mRNA decay 29 , nor did it alter the expression of transcription factors that govern helper T cell differentiation or CD4 + regulatory T cell proportions at tumour sites (Extended Data Fig. 7b-d) .
Immunosuppressive gene signatures driven by TGFβ1, PGE 2 and IL-10 signalling were predicted to be repressed in XBP1-deficient CD4 + T cells present in ovarian cancer ascites, whereas immuno-activating gene networks induced by ETS1, CD40 ligand engagement and protein kinases (such as RIPK2 and MAP3K14) were predicted to be activated in these cells (Extended Data Fig. 7e ). Accordingly, downstream cellular functions such as activation, proliferation and migration of immune cells were predicted to be induced in ascites-infiltrating CD4 + T cells that lack XBP1 (Extended Data Fig. 7f ). Mice lacking XBP1 in T cells that bore ovarian cancer had increased proportions of CD4 + T cells that secrete IFNγ at tumour sites, compared with their wild-type counterparts ( Fig. 4b , Extended Data Fig. 7g ). However, the frequency of infiltrating CD4 + T cells that produce IL-17 remained unaltered ( Fig. 4b ). Of note, only tumour-antigen-specific CD4 + T cells devoid of XBP1 demonstrated maximal IFNγ production in the ovarian cancer microenvironment (Fig. 4c ). XBP1-deficient intra-tumoral CD8 + T cells also showed enhanced effector profiles, as evidenced by increased perforin and IFNγ expression compared with their wildtype counterparts (Extended Data Fig. 7h , i). Ablation of XBP1 did not influence glucose import, but did increase the mitochondrial membrane potential of CD44 high CD4 + T cells at tumour sites, compared with the same T cell population from wild-type controls (Extended Data Fig. 7j , k). Expression of PD-1, CTLA-4 or TIM-3 was not altered (Extended Data Fig. 7l ), which suggests that the enhanced effector profile of XBP1-deficient T cells is likely to be independent of common immune checkpoint signalling. Overexpression of IFNγ emerged as a top biomarker of enhanced effector function by CD4 + T cells that lack XBP1. We sought to validate these findings in the human context. Exposure to ascites derived from patients with ovarian cancer dampened IFNγ production by CD4 + T cells (Extended Data Fig. 8a, b ), but disabling IRE1α-XBP1 with 4μ8C partly alleviated this effect and enhanced T cell mitochondrial respiration (Extended Data Fig. 8c-e ). 4μ8C had minimal effects on T cell viability or expression of T-bet or RORγt in CD4 + T cells exposed to ascites (Extended Data Fig. 8f-h) . Notably, enforcing SNAT1 expression in T cells also augmented their capacity to express IFNγ under glucose deprivation or exposure to ovarian cancer ascites (Extended Data Fig. 8i ).
We next assessed whether IRE1α-XBP1 activation in T cells influenced malignant progression. The growth of ovarian tumours driven by p53 loss and mutant KRAS 27 was compromised in female mouse hosts that have a haematopoietic compartment devoid of XBP1 selectively in T cells ( Fig. 4d ). Reduced tumour growth was also evidenced in Xbp1 f/f Cd4 cre female mice challenged with ID8-based ovarian cancer cells in the flank (Extended Data Fig. 7m ). Female mice that lack XBP1 in T cells showed decreased ascites accumulation and increased survival when challenged with metastatic ID8-Defb29/Vegfa tumours 28 (Fig. 4e ). Similar results were observed when these tumours were developed in Ern1 f/f Cd4 cre mice (Extended Data Fig. 7n ), which indicates that canonical IRE1α-XBP1 activation in T cells-rather than XBP1independent IRE1α kinase signalling or regulated IRE1α-dependent mRNA decay 29 -is responsible for the delayed ovarian cancer progression observed in XBP1-deficient mouse hosts. Ern1 f/f Cd4 cre mice that bear parental ID8 tumours 30 that do not overexpress Defb29 and Vegfa also showed reduced peritoneal carcinomatosis and extended survival, compared with their Ern1 f/f littermate controls ( Fig. 4f, g) .
Here we present experimental evidence that indicates that ovarian cancer exploits the IRE1α-XBP1 arm of the UPR to cripple T cell metabolism and anti-tumour capacity. The UPR normally facilitates adaptation to ER stress under nutrient-rich conditions; our findings suggest that T cells experience maladaptive IRE1α-XBP1 activation within tumours in which glucose availability is restricted (Extended Data Fig. 9 ). We propose that disruption of ER homeostasis in intratumoral T cells operates as an integrated 'immunometabolic checkpoint' that influences adaptive immunity and malignant progression in cancer hosts.
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No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment, unless stated otherwise. Patientderived specimens. Stage III and stage IV human ovarian carcinoma tumours and malignant ascites fluid were procured through Surgical Pathology at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center. The Weill Cornell Medicine IRB conducted a review of the project described and determined that the activities do not constitute human subjects research as these specimens were classified as surgical discard and remained completely de-identified. Collection and analysis of ovarian cancer specimens at Memorial Sloan Kettering Cancer Center were approved by an IRB protocol and were obtained under informed consent. Tumour single-cell suspensions were prepared as previously described 28 . Malignant ascites samples were centrifuged for 10 min at 1,300 r.p.m. Ascites supernatants were collected, depleted of cells by passing through 0.22-μm filters and stored frozen at −80 °C as small aliquots until use. Red blood cells in cell pellets were lysed with ACK lysing buffer (Gibco). Tumour infiltrating T cells (CD45 + CD20 − CD14 − CD3 + CD4 + or CD45 + CD20 − CD14 − CD3 + CD8 + ) were sorted from tumour single-cell suspensions or malignant ascites using a BD FACS Aria II SORP cell sorter at Flow Cytometry Core Facility in Weill Cornell Medicine. Dead cells were excluded using the LIVE/DEAD Fixable Yellow Dead Cell Stain Kit (Life Technologies). All specimens of ovarian cancer used and analysed in this study are described in Supplementary Table 1 . Transgenic mice and experimental ovarian cancer models. Mice devoid of XBP1 or IRE1α selectively in T cells were generated by breeding Xbp1 f/f or Ern1 f/f transgenic mice with the Cd4 cre strain 31,32 . All mouse strains are on a full C57BL/6 background and female mice were used at 6-8 weeks of age. Mice were housed in specific pathogen-free animal facilities at Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center. Mice were handled in compliance with Weill Cornell Institutional Animal Care and Use Committees procedures and guidelines. Gene-deficient mice were housed separately from wild-type littermate controls after genotyping at 3-4 weeks of age. Functional and survival experiments were conducted using age-matched littermate controls. In vivo experiments included three to six mice per group, based on transgenic genotype and sex availability. No randomization or blinding method was used for animal studies. Wild-type C57BL/6 mice were purchased from Jackson Laboratories.
'p53/KRAS' double transgenic animals were generated by crossing loxp-STOPloxp-Kras G12D/+ mice with p53 loxp/loxp mice as previously reported 27 . p53/KRAS mice were irradiated two consecutive days with 6.5 Gy followed by bone marrow transplantation from either Xbp1 f/f or Xbp1 f/f Cd4 cre mice. At eight weeks after bone marrow reconstitution, ovarian tumours were initiated by injecting Cre recombinaseexpressing adenovirus into the ovarian bursa. Tumour size was measured and volume was estimated using the formula V = 0.5 (length × width 2 ). Mice were euthanized nine weeks after tumour initiation and tumours were resected. Specimens were minced, digested for 1 h at 37 °C in RPMI containing 2 mg/ml collagenase D and 1 mg/ml DNase I and then passed through a 70-μm strainer to obtain single-cell suspensions. Red blood cells were eliminated using ACK lysis buffer (Gibco), and cell suspensions of 5-10 × 10 7 cells/ml were stored in freezing medium (FBS containing 10% DMSO) at −80 °C.
Parental ID8 cells expressing luciferase (ID8-Luc) or ovalbumin protein (ID8-OVA), and aggressive ID8-Defb29/Vegfa cancer cell-lines were generated as previously described 28, 30 . No authentication method was performed for the mouse cell lines used. All cell lines routinely tested negative for mycoplasma contamination using the Mycoplasma Detection Kit (Lonza) and maintained in medium containing plasmocin (Invivogen) for prophylactic purpose. In brief, 1.5 × 10 6 tumour cells were injected into the peritoneal cavity or right flank using Matrigel (Corning) of wild-type or transgenic mice described above. For live bioluminescent imaging, mice were given a single intraperitoneal injection of VivoGlo luciferin (Promega) and imaged with an IVIS Spectrum In Vivo imaging system at the Weill Cornell Research Animal Resource Center. To assess antigen-specific anti-tumour responses, Xbp1 f/f or Xbp1 f/f Cd4 cre female mice were independently challenged with ID8-Luc or ID8-OVA. Tumour-associated CD4 + T cells were simultaneously isolated from the peritoneal cavity of all mice 35 days after tumour challenge. Then, 5 × 10 5 T cells were co-cultured for 3 days with 1 × 10 5 BMDCs previously pulsed with OVA 323-339 peptide (1 μg/ml, InvivoGen). Cell culture supernatants were collected and IFNγ concentration was determined by enzyme-linked immunosorbent assay (ELISA) using the Ready-SET-Go kit (eBioscience).
To generate bone marrow chimaeras, recipient CD45.1 + C57BL/6 mice were fed with a Sulfatrim diet during 7 days before irradiation. Animals were then exposed to a single lethal dose of irradiation (10 Gy). Twenty-four hours later, 5 × 10 6 total bone marrow cells from a 1:1 mixture of wild-type CD45.1 + C57BL/6 and CD45.2 + Xbp1 f/f or Xbp1 f/f Vav1 cre bone marrow cells were injected intravenously into the irradiated recipient hosts. Mice were maintained on a Sulfatrim-based diet until the donor-derived cells in bone marrow and spleen were analysed by flow cytometry.
CD4 + T cell isolation and in vitro cell culture. Peripheral blood mononuclear cells from cancer-free female donors (New York Blood Center) were isolated by density-gradient centrifugation using Ficoll (GE Healthcare). CD4 + T cells were then enriched by negative selection using the human CD4 + T cell isolation kit (Miltenyi Biotech). Unless noted otherwise, CD4 + T cells were stimulated with Dynabeads human T-activator CD3 and CD28 (Thermo Fisher Scientific) at a 1:1 ratio for 16 h in the presence or absence of supernatants from ovarian cancer ascites, at the indicated concentrations. Depending on sample availability, all functional assays involving glucose uptake, IRE1α-XBP1 activation, bioenergetics and INFγ secretion were performed using CD4 + T cells obtained from at least 3 distinct donors that were independently exposed to ascites supernatants obtained from 2-7 different patients with ovarian cancer.
Mouse tumour-infiltrating T cells (CD45 + CD3 + CD4 + or CD45 + CD3 + CD8 + ) were sorted from various sources, including single-cell suspension of ovarian tumours driven by p53 and KRAS, spleen, draining lymph nodes and peritoneal wash, malignant ascites and spleen from mice bearing aggressive ID8-Defb29/ Vegfa ovarian cancer. Mouse splenic naive CD4 + T cells were isolated by negative selection (Miltenyi Biotech) and then activated with plate-bound anti-CD3ε (145-2C11, 5 μg/ml) and soluble anti-CD28 (37.51, 1 μg/ml; BD Pharmingen) antibodies for 48 h. All CD4 + T cells were cultured in complete RPMI, which is glucose-rich RPMI-1640 medium (Corning) further supplemented with 10% heat-inactivated FBS (Atlanta Biologicals), 2 mM l-glutamine (Corning), 25 mM HEPES, pH 7.2-7.6 (Corning), non-essential amino acids (Corning), 1 mM sodium pyruvate (Gibco), 100 IU penicillin and 100 μg/ml streptomycin (Corning) and 55 μM 2-mercaptoethanol (Gibco).
RNA extraction, reversetranscription PCR (RT-PCR), qPCR and XBP1 splicing assays.
Total RNA was isolated using RNeasy Mini kit or QIAzol lysis reagent (Qiagen) according to the manufacturer's instructions. Between 0.1 and 1 μg of RNA was reverse-transcribed to generate cDNA using the qScript cDNA synthesis kit (Quantabio). qPCR was performed using PerfeCTa SYBR green fastmix (Quantabio) and TaqMan Universal PCR master mix (Life Technologies) on a QuantStudio 6 Flex real-time PCR system (Applied Biosystems). Normalized gene expression was calculated by comparative threshold cycle method using ACTB, GAPDH or Actb as a control.
The XBP1 splicing assay was performed as previously described 33 . The PCR products were separated by electrophoresis through a 2.5% agarose gel and visualized by ethidium bromide staining. The ImageJ software for densitometry was used for calculating the frequency of XBP1 mRNA splicing (%) as follows: intensity of XBP1s band divided by (intensity of XBP1s + XBP1u band) × 100.
All primers and Taqman probes used in this study are described in Supplementary Table 3 . Analyses based on flow cytometry. Flow cytometry was conducted using fluorochrome-conjugated antibodies purchased from BioLegend, unless stated otherwise. For staining of mouse cells we used: anti-CD45 (30-F11), anti-CD4 (RM4-5), anti-CD8 (53-6.7), anti-CD3 (145-2C11), anti-TCRβ (H57-597), anti-CD44 (IM7), anti-CD62L (MEL-14), anti-CD11b (M1/70), anti-CD11c (N418), anti-CD19 (6D5), anti-F4/80 (BM8), anti-Ly6C (HK1.4), anti-Ly6G (1A8), anti-I-A/I-E (M5/114.15.2), anti-IFNγ (XMG1.2), anti-IL-17A (TC11-18H10.1), anti-FoxP3 (150D), anti-PD-1 (29F.1A12), anti-CTLA4 (UC10-4B9), anti-TIM3 (B8.2C12), TruStain fcX CD16/32 (93); anti-perforin (17-9392-80, eBioscience). To stain human cells we used: anti-CD45 (HI30), anti-CD3 (HIT3), anti-CD4 (A161A1), anti-CD8 (HIT8a), anti-CD20 (2H7), anti-CD14 (63D3), anti-IFNγ (4S. B3), anti-T-bet (4B10), TruStain FcX solution (422302); anti-XBP1s (Q3-695; BD Pharmingen); anti-RORγt (AFKJS-9, eBioscience). Staining of transcription factors XBP1s and FoxP3 and cytokines was carried out using FoxP3/transcription factor staining buffer set (eBioscience) according to the manufacturer's instructions. For in vitro glucose uptake experiments, 2 × 10 5 human CD4 + T cells were incubated with 20 μM 2-NBDG (Thermo Fisher Scientific) in glucose-free medium for 30 min at 37 °C. To measure levels of intracellular reactive oxygen species, cells were stained with 20 μM DCFDA (Abcam) for 30 min at 37 °C. The surface expression of GLUT1 in T cells residing in human ovarian cancer ascites was analysed using GLUT1.RBD.GFP (Metafora Biosystems) according to the manufacturer's instructions. In brief, 2 × 10 5 cells were labelled with 5 μl GLUT1.RBD.GFP in 100 μl of complete RPMI containing 0.09% NaN 3 and 1 mM EDTA and incubated for 30 min at 37 °C. Then cells were washed with PBS followed by cell-surface staining. To characterize ovarian cancer-infiltrating CD4 + T cells, peritoneal wash samples from Xbp1 f/f or Xbp1 f/f Cd4 cre female mice bearing metastatic ID8-Defb29/Vegfa ovarian cancer for 20-23 days were used. For intracellular cytokine staining, 5 × 10 6 cells from peritoneal wash samples were stimulated for 6 h in complete RPMI containing cell activation cocktail with brefeldin A (Biolegend). For 2-NBDG uptake in vivo, tumour-bearing mice were injected intraperitoneally with 100 μg 2-NBDG per mouse diluted in PBS and then, mice were euthanized 30 min after injection for collecting peritoneal cells. To measure mitochondrial membrane potential, peritoneal wash cells were stained with 200 nM TMRE (Thermo Fisher Scientific) Letter reSeArCH dye for 30 min at 37 °C followed by cell surface staining. To visualize proliferation assays, T cells were labelled with 5 μM CellTrace Violet (Thermo Fisher Scientific) at 37 °C for 30 min. The cell cycle of preactivated CD4 + T cells was analysed by staining DNA with 50 μg/ml propidium iodide solution containing 0.5 μg/ml RNase I after fixing the cells in cold 70% ethanol for 1 h at 4 °C. Forty-eight hours post-activation, CD4 + T cells were loaded with MitoTracker (20 nM, Thermo Fisher Scientific) to measure mitochondrial mass. All events were acquired on an LSRII (BD Biosciences) instrument and data were analysed with FlowJo software (TreeStar). Immunoblot analysis. T cells were washed twice in 1× cold PBS and cell pellets were lysed using RIPA lysis and extraction buffer (Thermo Fisher Scientific) supplemented with a protease and phosphatase inhibitor tablet (Roche). Homogenates were centrifuged at 14,000 r.p.m. for 30 min at 4 °C, and the supernatants were collected. Protein concentrations were determined using a BCA protein assay kit (Thermo Fisher Scientific). Equivalent amounts of protein were separated by SDS-PAGE and transferred onto PVDF membranes following the standard protocol. The following antibodies were used: anti-GLUT1 (D3J3A), anti-ACTB (4967S), anti-ASCT2 (V501) and anti-SNAT1/SLC38A1 (D9L2P) (Cell Signaling Technologies); anti-PGC-1α (H-300) and anti-SNAT2 (C-6) (Santa Cruz Biotechnology); and goat anti-rabbit and mouse secondary antibodies conjugated with HRP (Thermo Fisher Scientific). SuperSignal West Pico and Femto chemiluminescent substrates (Thermo Fisher Scientific) were used to image blots in a FluorChemE instrument (ProteinSimple). The proteasomal inhibitor MG132 (10 μM, Sigma) and translation inhibitor cycloheximide (CHX, 50 μg/ml, Sigma) were used to assess protein abundance and stability. Densitometric quantification was performed using Image J software (NIH). Seahorse analyses. Purified CD4 + T cells from cancer-free female donors were stimulated with human T-activator CD3 and CD28 Dynabeads (Life Technologies) in complete RPMI medium containing 10% FBS, in the presence or absence of supernatants from ovarian cancer ascites for 16 h. The effect of IRE1α inhibition using 4μ8C (10 μM, EMD Millipore) or GlcNAc supplementation (10 mM, Sigma) was examined by pre-treating T cells 1-2 h before addition of human ovarian cancer ascites. DMKG (5 mM, Sigma) was added in the cell culture during the final 4 h of incubation. After incubation, T cells were collected, thoroughly washed and then subjected to Seahorse analyses using non-buffered XF base medium containing 25 mM glucose (Sigma), 2 mM l-glutamine, and 1 mM sodium pyruvate but lacking serum or ascites. XF96 cell-culture microplates were coated with CellTak (Corning) before analysis according to the manufacturer's instructions and washed twice with distilled water. Unless stated otherwise, 1.5 × 10 5 T cells were plated and OCR and ECAR measurements were analysed on an XFe96 Extracellular Flux Analyzer (Agilent). After basal OCR and ECAR measurements were obtained, an OCR trace was recorded in response to oligomycin (1 μM), carbonyl cyanide-p-(trifluoromethoxy) phenylhydrazone (FCCP, 1 μM), and rotenone and antimycin (0.5 μM each) following the XF Cell Mito Stress test kit (Agilent). To evaluate mitochondrial fuel usage, T cells were seeded in the Seahorse medium containing 2 mM l-glutamine ± 25 mM glucose. After recording basal OCR and ECAR measurements, cells were injected with corresponding base medium (control), UK5099 (2 μM), BPTES (3 μM) and etomoxir (4 μM) using the XF Mito Fuel Flex test kit (Agilent) followed by oligomycin, FCCP, and rotenone and antimycin injection. Metabolic parameters were calculated as follow: basal OCR = last rate measurement before oligomycin injection -minimum rate measurement after rotenone and antimycin injection; maximal OCR = maximum rate measurement after FCCP injection -minimum rate measurement after rotenone and antimycin injection. Typically, 3-6 technical replicates per each sample were examined. After analysis, the cell numbers of each well were determined by nuclear DNA staining with Hoechst 33342 (Sigma) and OCR and ECAR values were normalized accordingly. Glutamine tracing experiments. For stable isotope tracer experiments, naive splenic CD4 + T cells isolated from wild-type or XBP1-deficient mice were activated by CD3 and CD28 stimulation for 48 h, followed by culture in the presence or absence of glucose for 4.5 h, and then pulsed with [U-13 C]glutamine (Sigma) for an additional 1.5 h in the same culture condition. After washing twice with cold PBS, metabolites were extracted from the cells by methanol extraction method 34 . In brief, pre-cooled 80% methanol (1 ml) was added to each sample and kept in −80 °C for 20 min. Samples were then centrifuged at 4 °C for 5 min at 14,000 r.p.m. The supernatants were extracted and normalized based on cell amount. Targeted liquid chromatography-mass spectrometry (LC-MS) analyses were performed on a Q Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific) coupled to a Vanquish UPLC system (Thermo Fisher Scientific). The Q Exactive operated in polarity-switching mode. A Sequant ZIC-HILIC column (2.1 mm i.d. × 150 mm, Merck) was used for separation of metabolites. Flow rate was set at 150 μl/min. Buffers consisted of 100% acetonitrile for mobile A, and 0.1% NH 4 OH and 20 mM CH 3 COONH 4 in water for mobile B. Gradient ran from 85% to 30% A in 20 min followed by a wash with 30% A and re-equilibration at 85% A. Metabolites were identified on the basis of exact mass within 5 p.p.m. and standard retention times.
Relative metabolite quantitation was performed based on peak area for each metabolite. Tracing experiments were performed at the Proteomics and Metabolomics Core Facility of Weill Cornell Medicine. Immunofluorescence and confocal microscopy. Cells were transferred onto polyl-lysine pre-coated glass coverslips (Neuvitro) and incubated at 37 °C for 30 min. The coverslips were washed with cold PBS three times between each step. Cells were immediately fixed with ice-cold acetone for 10 min at room temperature. Then, the coverslips were blocked for 1 h in PBS containing 0.25% Triton X-100 and 5% FBS at 4 °C, followed by incubation at 4 °C overnight with primary antibodies rabbit anti-ASCT2 (V501, Cell Signaling Technologies, 1:200) and mouse anti-SNAT2 (C-6) (Santa Cruz Biotechnology, 1:200) in PBS containing 5% FBS, protected from light. Then, secondary antibodies Alexa Fluor 488-conjugated goat anti-rabbit IgG and Alexa Fluor 594-conjugated goat anti-mouse IgG (Molecular Probes, 1:400) were added for 1 h at room temperature in the dark. Cells were counterstained with 4′,6-diamidino-2-phenylindole (DAPI, Thermo Fisher Scientific, 0.5 μg/ml) for 5 min at room temperature in the dark. After washing and removing excess solution, the flipped coverslips were placed on the mounting medium (Southern Biotechnology). Slides were allowed to dry in the dark for 1 h in a humid chamber at room temperature. Slides were then sealed with fingernail polish before examination. Digital confocal images were captured on a Zeiss LSM 880 Confocal Microscope with the Airy Scan high-resolution detector at the Weill Cornell CLC Imaging Core Facility. Image J software was used to determine the average pixel intensity of 16-bit greyscale images from each channel, individually. A region of interest was drawn around an individual cell that was not in contact with other cells, and the mean intensity was recorded. Approximately 50 cells in a field from three independent slides were quantified to calculate average fluorescence intensity (n = 150 total cells). Retroviral transduction. The coding region of SLC38A1 (NM_001278387.1), the gene encoding human SNAT1, was amplified using cDNA that originated from healthy peripheral blood mononuclear cells as a template and the following PCR primers: 5′-GAATTCGCCACCATGATGCATTTCAAAAGTGGACTCGA-3′ (forward); 5′-GCGGCCGCTCAGTGGCCTTCGTCACTACTCG-3′ (reverse). The PCR product was cloned into the pBMN-I-GFP retroviral-expressing vector (Addgene) and subsequently transfected into the Phoenix-AMPHO (ATCC) retrovirus producer cell line using Lipofectamine 3000 (Invitrogen) to generate retroviruses. Cell-culture supernatants containing virus were collected at 48 h and 72 h post-transfection. The virus was then bound to 24-well non-tissue-culture-treated plates previously coated with RetroNectin (70 μg/ml, Takara Bio) by centrifugation at 2,000g for 2 h at 37 °C. Human CD4 + T cells were stimulated with anti-CD3 and anti-CD28 Dynabeads (Life Technologies) in the presence of recombinant human IL-2 (50 units per ml, PeproTech) for 36 h before viral transduction. Typically, 1 × 10 6 T cells were added to each virus-coated well by brief centrifugation at a final concentration of 2 × 10 6 cells per ml containing 50 units per ml of IL-2 and second transduction was followed 24 h later as the same strategy. GFP + cells were sorted 48 h post-transfection and expanded with anti-CD3 and anti-CD28 stimulation in the presence of IL-2 for additional 48 h, for downstream assays. ELISA. Eighty thousand human CD4 + T cells were activated for 12 h and subsequently incubated for additional 36 h in the presence of 25% ascites. To test the effect of IRE1α inhibition on IFNγ secretion, T cells were activated for 36 h, treated with 4μ8C at 10 μM (or DMSO control) 2 h before adding 25% human ovarian cancer ascites, and incubated for additional 10 h. The concentration of IFNγ in culture supernatants was determined by ELISA using the Ready-SET-Go kit (eBioscience). IFNγ was undetectable in ascites supernatants when used at 25%. Cell viability and counts were comparable in all cases. RNA sequencing and transcriptional profiling. Tumour infiltrating CD4 + T cells (CD45 + CD3 + CD4 + ) were sorted from peritoneal wash samples of Xbp1 f/f or Xbp1 f/f Cd4 cre female mice bearing aggressive ID8-Defb29/Vegfa ovarian cancer for 20 days. CD44 high CD62L low CD4 + T cells were sorted from the spleen of naive Xbp1 f/f or Xbp1 f/f Cd4 cre female mice. miRVana miRNA isolation kit (Ambion) and RNeasy MinElute kit (Qiagen) were used for total RNA isolation and concentration. All samples were passed RNA quality controls examined by Agilent Bioanalyzer 2100, and mRNA libraries were generated and sequenced at the Weill Cornell Epigenomics Core Facility.
Reads produced from 51-bp single-end sequencing runs were aligned against mouse genome (mm9) using Bowtie v.0.12.8 algorithm 35 . Mouse mm9 transcriptome information was obtained from UCSC Genome Browser 36 and the RSEM algorithm 37 was used to calculate number of aligned tags for each gene. Differential expression between two groups were tested by EdgeR 38 and genes that had at least 50 raw counts and passed FDR cut-off of 15% with at least 1.5-fold difference were considered significant. Official symbol and gene description information was obtained from NCBI Entrez information 39 . Normalized expression values of reads per kilobase of transcript per million mapped reads were generated by EdgeR and used to demonstrate gene expression across samples as a colour-coded fold change in expression in a sample, versus average expression across all samples. Functional enrichment analysis was done using Ingenuity Pathway Analysis (Qiagen).
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Extended Data Fig. 8 | IRE1α-XBP1 regulates IFNγ production in human CD4 + T cells exposed to ascites. a, IFNG expression in CD4 + T cells receiving CD3 and CD28 activation for 16 h under increasing concentrations of supernatants of ovarian cancer ascites; 10% (n = 12); 50% (n = 3); 100% (n = 3). b, CD4 + T cells were activated for 12 h, incubated for additional 36 h in the presence of 25% ascites, and IFNγ in culture supernatants was determined by ELISA. Data were normalized to final viable cell counts in each case. n = 11 independent responder CD4 + T cells in all cases with the exception of A14 (n = 9), A15 (n = 10) and A17 (n = 3). c-h, Pre-activated CD4 + T cells were treated with 4μ8C for 2 h, and 25% ascites was subsequently added to the culture for additional 12 h. c, IFNγ in culture supernatants was quantified by ELISA (n = 14). Data are presented as relative expression compared with matching controls that were not exposed to ascites. d, FACS histogram (left) and quantitative analysis (right) for intracellular IFNγ in CD4 + T cells (n = 16). e, Maximal OCR presented as per cent response change compared with untreated controls (n = 7). f, The frequency of viable cells among total cells was determined by staining with dead cell exclusion dye (n = 12). The frequency of T-bet + (g) and RORγt + (h) populations among CD4 + T cells was determined by intracellular staining and presented as relative expression compared with controls that were not treated with ascites (n = 12). i, IFNG expression by SNAT1-overexpressing human CD4 + T cells exposed to 10% ovarian cancer ascites (n = 6 from two independent experiments) or incubated in glucose-free medium (n = 3 from two independent experiments). Data were normalized to endogenous expression of GAPDH in each sample. Data are presented as relative expression compared with control-virus-transduced T cells that were not exposed to ascites or glucose-deprived. Data are shown as mean ± s.e.m. (a-c, f-i) . n values represent biologically independent samples (a-i). One-way ANOVA with Bonferroni's multiple comparisons test (a, b); oneway ANOVA with Tukey's multiple comparisons test (c, f-h); two-tailed paired Student's t-tests (d, e); two-tailed Student's t-tests (i); *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; gMFI, geometric mean fluorescence intensity.
Extended data table 1 | defective N-linked protein glycosylation in Cd4 + t cells exposed to ascites CD4 + T cells were activated with anti-CD3 and anti-CD28 beads in the presence or absence of ascites for 16 h. Cells were lysed and the enriched glycoprotein fractions were analysed for N-linked glycosylation events by LC-MS/MS. Representative glycoproteins recovered from both control and ascites-exposed CD4 + T cells. The table shows each site for N-linked glycosylation on the identified protein, the glycan type on that site and the number of glycosylation events identified in each glycoform. The per cent decrease in glycosylation upon ascites exposure was calculated using the following equation: per cent decrease in glycosylation = 100 -(number of total glycosylation eventsascites divided by the number of total glycosylation eventscontrol) × 100. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
Sample sizes were determined based on the results of pilot studies, which indicated the potential standard deviation of responses under a 95% confidence level (Z-score=1.96). For most functional in vitro analyses, sample sizes were chosen based on the availability of target cells.
Functional animal experiments used between three and six mice per group, based on transgenic genotype and sex availability. Since this study focuses on ovarian cancer, only female mice were included in the experimental design.
Data exclusions All samples that met adequate experimental conditions were included in the analysis.
-To test the effect of 4 8C on human T cell bioenergetics and IFN-secretion, we included specimens wherein ascites exposure effectively decreased basal OCR or IFN-secretion (87.5% and 73% inclusion rate, respectively), compared with corresponding untreated controls.
-For survival experiments, mice that did not develop ovarian cancer were excluded from the analysis. This occurred in less than 5% of the cases.
Replication
Experiments were performed at least two times and/or with sufficient cells/animals per group to demonstrate statistical significance.
Randomization -The experiments were not randomized. Peripheral blood from de-identified female donors without cancer were acquired and analyzed.
-Metastatic ovarian cancer ascites supernatants were also obtained from de-identified patients and were not randomized.
-Animals were not intentionally randomized. All animal experiments were conducted using 6-8 week-old female mice with age-matched littermate controls. Mice were housed separately from littermate controls after genotyping at 3-4 weeks of age.
Blinding
-After setting up the in vitro experiments, each sample often assigned a code number to facilitate blinded quantitative gene expression, flow cytometric, bioenergetic, confocal microscopic and transmission electron microscopic analyses. After all data were collected, the results were analyzed and decoded.
-To quantify the mean fluorescence intensity (MFI) of each glutamine transporter by immunofluorescence analysis, ~50 individual cells from three independent slides (n = 150) was computationally quantified using the Image J software by two independent investigators in a blinded manner.
-No blinding method was used for animal studies.
Reporting for specific materials, systems and methods P53/K-ras mice were irradiated two consecutive days with 650 rads followed by bone marrow transplantation from either Xbp1f/ f or Xbp1f/f Cd4cre mice. At 8 weeks post bone marrow reconstitution, ovarian tumors were initiated by injecting Cre recombinase-expressing adenovirus into the ovarian bursa. Tumor size was measured and volume was estimated using the formula V = 0.5 (Length × Width2). Mice were sacrificed 9 weeks after tumor initiation and tumors were resected. Specimens were minced, digested for 1h at 37°C in RPMI containing 2mg/ml collagenase D and 1mg/ml DNAse I and then passed through a 70μm strainer to obtain single cell suspensions. Red blood cells were eliminated using ACK lysis buffer (Gibco), and cell suspensions of 5-10 × 10^7 cells/ml were stored in freezing media (FBS containing 10% DMSO) at -80°C. -1.5 × 10^6 OvCa cell lines including parental ID8 cells expressing luciferase (ID8-Luc) or ovalbumin protein (ID8-Ova), or aggressive ID8-Defb29/Vegfa were injected into the peritoneal cavity or right flank using Matrigel (Corning) of WT or transgenic mice described above.
-For live bioluminescent imaging, mice were given a single intraperitoneal injection of VivoGlo luciferin (Promega) and imaged with an IVIS Spectrum In Vivo imaging system at the Weill Cornell Research Animal Resource Center.
-To generate bone marrow chimeras, recipient CD45.1+ C57BL/6 mice were fed with a Sulfatrim diet during 7 days prior to irradiation. Animals were then exposed to a single lethal dose of irradiation (1,000rads). 24 h later, 5 × 106 total bone marrow cells from a 1:1 mixture of wild-type CD45.1+ C57BL/6 and CD45.2+ Xbp1f/f or Xbp1f/f Vav1cre bone marrow cells were injected intravenously into the irradiated recipient hosts. Mice were maintained on a Sulfatrim-based diet until analyzing the donorderived cells in bone marrow and spleen by flow cytometry.
Wild animals
No wild animals were used in the study.
Field-collected samples
No field-collected samples were used.
Human research participants
Policy information about studies involving human research participants Population characteristics -The Weill Cornell Medicine IRB conducted a review of the project described and determined that the activities do not constitute human subjects research. All specimens were classified as surgical discard and remained totally de-identified. Stage III-IV human ovarian carcinoma specimens and malignant ascites samples were procured through Surgical Pathology and the Division of Gynecologic Oncology at Weill Cornell Medical College/NewYork-Presbyterian Hospital. Collection and analysis of ovarian cancer specimens obtained at Memorial Sloan Kettering Cancer Center were approved by an institutional IRB protocol. A universal consent form was obtained for all subjects. All OvCa specimens analyzed in this study are described in Supplementary  Table 1 .
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-We obtained randomly selected peripheral blood mononuclear cells (PBMCs) from de-identified, cancer-free female donors (New York Blood Center).
Recruitment None
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Methodology
Sample preparation -Solid tumor specimens were prepared to obtain single cell suspensions as previously described (ref. 28) . Malignant ascites samples were centrifuged for 10 min at 1,300rpm. Red blood cells in cell pellets were lysed with ACK lysing buffer (Gibco). Peripheral blood mononuclear cells (PBMCs) from cancer-free female donors were isolated by density gradient centrifugation using Ficoll (GE Healthcare). All cell suspensions were passed through 40um strainers to remove remaining large aggregates. All the Fc receptors were blocked using Fc blocking reagents 30 min in prior to adding antibody mixtures.
-Surface antigen staining was performed in PBS supplemented with 2mM EDTA and 1% FBS, and dead cells were excluded using DAPI. For intracellular staining, cells were typically stained using LIVE/DEAD Fixable Cell Stain Kit (Life Technologies), followed by surface staining and intracellular staining using FoxP3/Transcription factor staining buffer set (eBioscience) according to manufacturer's instructions. To determine cytokine production, cells were stimulated for 6 h in complete RPMI containing cell activation cocktail with brefeldin A (Biolegend).
Instrument
Cells were sorted using a BD FACSAria II SORP cell sorter at Flow Cytometry Core Facility in Weill Cornell Medicine. All flow cytometry-based analyses were carried out using LSR II (BD Biosciences).
Software
All events were acquired using BD FACS Diva software and data were analyzed with FlowJo software v.10 (TreeStar).
Cell population abundance Post-sort fractions were above 95% in purity as determined by a post-sort purity check.
Gating strategy -To sort T cells from various sources, cells were first gated on the basis of FSC-A/SSC-A and then singlets were gated based on FSC-W/FSC-H and/or SSC-W/SSC-H. Cells that were positive for viability dye staining were excluded. Next, CD45 positive gating was used for leukocyte selection. Subsequently, CD3+ CD4+ or CD3+ CD8+ T cells were collected from CD14 and CD20 double negative cells.
-Cytokine-producing populations were determined by comparing cells stained using isotype controls.
-To sort GFP+ T cells from retrovirus-transduced CD4+ T cells, cells were gated on FSC-A/SSC-A basis, and then singlets were gated based on FSC-W/FSC-H. Next, GFP-expressing cells were collected from CD3+ CD4+ cells where non-transduced cells were used as negative control.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
